FATE THERAPEUTICS INC — Form 8-K
Filed September 28, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Fate Therapeutics received a $15.0 million grant from California Institute for Regenerative Medicine (CIRM) through its competitive CLIN2 program to support RECLAIM-LN, a Phase 2 potentially registrational trial of FT819 off-the-shelf CAR T-cell therapy in patients with refractory lupus nephritis. The trial will enroll approximately 53 patients with the primary endpoint of complete renal response at Week 26. No counterparties, equity dilution, or share issuances were disclosed.
Why this rating
Grant equals ~13% of market cap; meaningful non-dilutive funding for clinical-stage biotech with significant unmet-need indication (150K lupus nephritis patients). RMAT designation and CDRP selection support regulatory pathway, but clinical trial success unproven.
See more from September 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.